Oyster peptide composition capable of improving sexual function of male and preparation method thereof
A technology of oyster peptide and composition, applied in the field of oyster peptide composition for improving male sexual function and its preparation field, can solve the problems of increased miscarriage and congenital defect rate, decreased survival rate of pups, poor reproductive function, etc. Effects of sexual dysfunction, reduction of prostate disease, ease of industrial production
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0037] Embodiment 1 improves premature ejaculation test
[0038] (1) Volunteer selection criteria
[0039] ① The patient is a male aged 18 to 50 years.
[0040] ② Maintain a single and stable sexual relationship with the same woman for at least 6 months.
[0041] ③Conform to the diagnostic criteria for PE in the "Diagnostic and Statistical Manual of Mental Disorders-Fourth Edition" promulgated by the American Psychiatric Association.
[0042] (2) Treatment plan
[0043] Treatment group: Tablets prepared in Example 4 of the composition of the present invention, 55 cases in total.
[0044] Control group: Vigorous Oyster Tablets group, a total of 55 cases.
[0045] (3) How to use
[0046] Both groups are taken orally, and used half an hour before sexual intercourse, and combined use is prohibited. The treatment group took 2 tablets twice a day for 4 consecutive weeks; the control group used it according to the instructions. The frequency of sex life is required to be once ...
Embodiment 2
[0054] Embodiment 2 improves erectile dysfunction
[0055] The 100 patients were all outpatients in the hospital. The oldest age was 63 years old, and the youngest age was 27 years old. Among them, 23 cases were 27-30 years old, 50 cases were 31-40 years old; 21 cases were 41-50 years old, and 6 cases were over 51 years old. The shortest is 1 month and the longest is 12 years. The selection criteria of patients were formulated according to the first volume of "Guiding Principles for Clinical Research of New Chinese Medicines" (1993). The main clinical manifestation of the patient is male sexual dysfunction.
[0056] 2. Diagnostic criteria: the penis cannot get erection or the erection is not firm, and the person who cannot complete sexual intercourse.
[0057] 3. Treatment method
[0058] All patients are administered capsules prepared according to the formula in Example 4 of the present invention, each 4 tablets, three times a day, taken with warm water; 2 weeks is 1 cours...
Embodiment 3
[0069] Embodiment 3 improves sperm motility test
[0070] 1. Test equipment and reagents
[0071] Cyclophosphamide was purchased from Jiangsu Hengrui Medicine Co., Ltd.; testosterone (T) radioimmunoassay kit, mouse follicle-stimulating hormone (FSH) radioimmunoassay kit, mouse luteinizing hormone (LH) radioimmunoassay kit , were purchased from Atom High Technology Co., Ltd.
[0072] 2. Experimental method
[0073] 2.1 Research object
[0074] Thirty clean-grade male SD rats were randomly divided into control group (intraperitoneal injection of purified water), model group (intraperitoneal injection of cyclophosphamide), and test group with 10 rats in each group. The oligospermia model was made by intraperitoneal injection of cyclophosphamide.
[0075] 2.2 Experimental method
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com